Bank of America is reiterating its $116 price objective on shares of Biogen BIIB.
“Our report today outlines analyses that support a strong competitive profile for BIIB's late stage oral multiple sclerosis drug candidate BG-12, and we reiterate our $116 PO ahead of key data catalysts this fall,” Bank of America writes. “BIIB shares have lost ground as investors are concerned that detailed Phase 3 data and/or a second Phase 3 data will not live up to expectations.
“Our analysis suggests that BG-12 may have one of the best oral multiple sclerosis profiles and prove longer term an alternative to current standard injectable therapy. Thus, we continue to believe BG-12 should have an important role in front-line multiple sclerosis treatment (est 15 20% peak market share).”
Biogen closed Monday at $91.78.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in